Madrigal Pharmaceuticals (0JXI) Share Forecast & Price Target

Compare

0 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

0JXI Analyst Ratings

Strong Buy

16 Buy

1 Hold

0 Sell

Based on 17 analysts giving stock ratings to

Madrigal

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

0JXI Stock 12 Month Forecast

Average Price Target

$519.64

▲(7.01% Upside)

Based on 17 Wall Street analysts offering 12 month price targets for Madrigal Pharmaceuticals in the last 3 months. The average price target is $519.64 with a high forecast of $590.00 and a low forecast of $392.00. The average price target represents a 7.01% change from the last price of $485.58.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"209":"$209","400":"$400","591":"$591","304.5":"$304.5","495.5":"$495.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":590,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$590.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":519.64,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$519.64</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":392,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$392.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[209,304.5,400,495.5,591],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,459.5,469.53846153846155,479.5769230769231,489.61538461538464,499.65384615384613,509.6923076923077,519.7307692307693,529.7692307692307,539.8076923076923,549.8461538461538,559.8846153846154,569.9230769230769,579.9615384615385,{"y":590,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,459.5,464.12615384615384,468.7523076923077,473.3784615384615,478.00461538461536,482.6307692307692,487.25692307692304,491.88307692307694,496.5092307692308,501.1353846153846,505.76153846153846,510.3876923076923,515.0138461538461,{"y":519.64,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,459.5,454.3076923076923,449.11538461538464,443.9230769230769,438.7307692307692,433.53846153846155,428.34615384615387,423.15384615384613,417.96153846153845,412.7692307692308,407.5769230769231,402.38461538461536,397.1923076923077,{"y":392,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":210.93,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":314.439,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":325,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":314.796,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":336.77,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":338.19,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":329.273,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":329.39,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":272.72,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":297.91,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":301.62,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":434.523,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":459.5,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$590.00

Average Price Target$519.64

Lowest Price Target$392.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Yasmeen Rahimi

Piper Sandler

$400→$540

Buy

11.21%

Upside

Reiterated

10/15/25

Madrigal Pharmaceuticals price target raised to $540 from $400 at Piper SandlerMadrigal Pharmaceuticals price target raised to $540 from $400 at Piper Sandler

Srikripa Devarakonda

Truist Financial

$580

Buy

19.44%

Upside

Initiated

10/15/25

Madrigal Pharmaceuticals: Strong Growth Potential Driven by Rezdiffra's Market Leadership and Strategic Opportunities

Jay Olson

Oppenheimer

$500→$590

Buy

21.50%

Upside

Reiterated

10/10/25

Madrigal Pharmaceuticals (MDGL) Gets a Buy from Oppenheimer

William Wood

B. Riley Securities

$460→$560

Buy

15.33%

Upside

Reiterated

09/29/25

Madrigal Pharmaceuticals price target raised to $560 from $460 at B. RileyMadrigal Pharmaceuticals price target raised to $560 from $460 at B. Riley

Eliana Merle

UBS

$523

Buy

7.71%

Upside

Reiterated

09/24/25

Madrigal Pharmaceuticals (MDGL) Gets a Buy from UBS

Edward Nash

Canaccord Genuity

$428→$526

Buy

8.32%

Upside

Reiterated

09/12/25

Madrigal Pharmaceuticals (MDGL) Receives a Buy from Canaccord Genuity

Andrew Fein

H.C. Wainwright

$500

Buy

2.97%

Upside

Initiated

09/04/25

Madrigal Pharmaceuticals assumed with a Buy at H.C. WainwrightMadrigal Pharmaceuticals assumed with a Buy at H.C. Wainwright

Ritu Baral

TD Cowen

$390→$554

Buy

14.09%

Upside

Reiterated

08/25/25

TD Cowen Sticks to Their Buy Rating for Madrigal Pharmaceuticals (MDGL)

Prakhar Agrawal

Cantor Fitzgerald

―

Hold

―

Reiterated

08/22/25

Cantor Fitzgerald Sticks to Their Hold Rating for Madrigal Pharmaceuticals (MDGL)

Michael DiFiore

Evercore ISI

$392

Buy

-19.27%

Downside

Initiated

08/22/25

Evercore ISI Sticks to Its Buy Rating for Madrigal Pharmaceuticals (MDGL)

Jonathan Wolleben

Citizens JMP

$483→$485

Buy

-0.12%

Downside

Reiterated

08/20/25

Madrigal Pharmaceuticals price target raised to $485 from $483 at Citizens JMPMadrigal Pharmaceuticals price target raised to $485 from $483 at Citizens JMP

Thomas Smith

Leerink Partners

―

Buy

―

Reiterated

08/19/25

Madrigal Pharmaceuticals: Pioneering MASH Treatment with Rezdiffra's European Market Breakthrough

Jason Zemansky

Bank of America Securities

$266

Sell

-45.22%

Downside

Reiterated

08/19/25

Analysts Offer Insights on Healthcare Companies: CytomX Therapeutics (NASDAQ: CTMX), Madrigal Pharmaceuticals (NASDAQ: MDGL) and VolitionRX (NYSE MKT: VNRX)

David Lebowitz

Citi

$505

Buy

4.00%

Upside

Assigned

08/19/25

Buy Rating Affirmed for Madrigal Pharmaceuticals Amid Market Expansion Opportunities

Andrea Tan

Goldman Sachs

$567

Buy

16.77%

Upside

Reiterated

08/18/25

Goldman Sachs Sticks to Its Buy Rating for Madrigal Pharmaceuticals (MDGL)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Yasmeen Rahimi

Piper Sandler

$400→$540

Buy

11.21%

Upside

Reiterated

10/15/25

Madrigal Pharmaceuticals price target raised to $540 from $400 at Piper SandlerMadrigal Pharmaceuticals price target raised to $540 from $400 at Piper Sandler

Srikripa Devarakonda

Truist Financial

$580

Buy

19.44%

Upside

Initiated

10/15/25

Madrigal Pharmaceuticals: Strong Growth Potential Driven by Rezdiffra's Market Leadership and Strategic Opportunities

Jay Olson

Oppenheimer

$500→$590

Buy

21.50%

Upside

Reiterated

10/10/25

Madrigal Pharmaceuticals (MDGL) Gets a Buy from Oppenheimer

William Wood

B. Riley Securities

$460→$560

Buy

15.33%

Upside

Reiterated

09/29/25

Madrigal Pharmaceuticals price target raised to $560 from $460 at B. RileyMadrigal Pharmaceuticals price target raised to $560 from $460 at B. Riley

Eliana Merle

UBS

$523

Buy

7.71%

Upside

Reiterated

09/24/25

Madrigal Pharmaceuticals (MDGL) Gets a Buy from UBS

Edward Nash

Canaccord Genuity

$428→$526

Buy

8.32%

Upside

Reiterated

09/12/25

Madrigal Pharmaceuticals (MDGL) Receives a Buy from Canaccord Genuity

Andrew Fein

H.C. Wainwright

$500

Buy

2.97%

Upside

Initiated

09/04/25

Madrigal Pharmaceuticals assumed with a Buy at H.C. WainwrightMadrigal Pharmaceuticals assumed with a Buy at H.C. Wainwright

Ritu Baral

TD Cowen

$390→$554

Buy

14.09%

Upside

Reiterated

08/25/25

TD Cowen Sticks to Their Buy Rating for Madrigal Pharmaceuticals (MDGL)

Prakhar Agrawal

Cantor Fitzgerald

―

Hold

―

Reiterated

08/22/25

Cantor Fitzgerald Sticks to Their Hold Rating for Madrigal Pharmaceuticals (MDGL)

Michael DiFiore

Evercore ISI

$392

Buy

-19.27%

Downside

Initiated

08/22/25

Evercore ISI Sticks to Its Buy Rating for Madrigal Pharmaceuticals (MDGL)

Jonathan Wolleben

Citizens JMP

$483→$485

Buy

-0.12%

Downside

Reiterated

08/20/25

Madrigal Pharmaceuticals price target raised to $485 from $483 at Citizens JMPMadrigal Pharmaceuticals price target raised to $485 from $483 at Citizens JMP

Thomas Smith

Leerink Partners

―

Buy

―

Reiterated

08/19/25

Madrigal Pharmaceuticals: Pioneering MASH Treatment with Rezdiffra's European Market Breakthrough

Jason Zemansky

Bank of America Securities

$266

Sell

-45.22%

Downside

Reiterated

08/19/25

Analysts Offer Insights on Healthcare Companies: CytomX Therapeutics (NASDAQ: CTMX), Madrigal Pharmaceuticals (NASDAQ: MDGL) and VolitionRX (NYSE MKT: VNRX)

David Lebowitz

Citi

$505

Buy

4.00%

Upside

Assigned

08/19/25

Buy Rating Affirmed for Madrigal Pharmaceuticals Amid Market Expansion Opportunities

Andrea Tan

Goldman Sachs

$567

Buy

16.77%

Upside

Reiterated

08/18/25

Goldman Sachs Sticks to Its Buy Rating for Madrigal Pharmaceuticals (MDGL)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Madrigal Pharmaceuticals

1 Month

xxx

Success Rate

11/15 ratings generated profit

Average Return

+30.33%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 73.33% of your transactions generating a profit, with an average return of +30.33% per trade.

3 Months

xxx

Success Rate

11/14 ratings generated profit

Average Return

+14.96%

reiterated a xxx

rating 8 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 78.57% of your transactions generating a profit, with an average return of +14.96% per trade.

1 Year

Ritu BaralTD Cowen

Success Rate

20/22 ratings generated profit

Average Return

+43.48%

reiterated a buy rating 3 days ago

Copying Ritu Baral's trades and holding each position for 1 Year would result in 90.91% of your transactions generating a profit, with an average return of +43.48% per trade.

2 Years

xxx

Success Rate

14/14 ratings generated profit

Average Return

+130.34%

reiterated a xxx

rating 8 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +130.34% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0JXI Analyst Recommendation Trends

Rating

Jun 25

Jul 25

Aug 25

Sep 25

Oct 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0JXI has received 24 Buy Ratings, 1 Hold Ratings, and 2 Sell Ratings. 0JXI average Analyst price target in the past 3 months is 519.64.

Each month's total comprises the sum of three months' worth of ratings.

0JXI Financial Forecast

0JXI Earnings Forecast

Next quarter’s earnings estimate for 0JXI is -$0.66 with a range of -$6.09 to $1.96. The previous quarter’s EPS was -$5.08. 0JXI beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year 0JXI has Preformed in-line its overall industry.

0JXI Sales Forecast

Next quarter’s sales forecast for 0JXI is $310.02M with a range of $285.28M to $320.10M. The previous quarter’s sales results were $287.27M. 0JXI beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year 0JXI has Preformed in-line its overall industry.

0JXI Stock Forecast FAQ

What is GB:0JXI’s average 12-month price target, according to analysts?

Based on analyst ratings, Madrigal Pharmaceuticals Inc’s 12-month average price target is 519.64.

What is GB:0JXI’s upside potential, based on the analysts’ average price target?

Madrigal Pharmaceuticals Inc has 7.01% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Madrigal Pharmaceuticals Inc a Buy, Sell or Hold?

Madrigal Pharmaceuticals Inc has a consensus rating of Strong Buy, which is based on 16 buy ratings, 1 hold ratings and 0 sell ratings.

What is Madrigal Pharmaceuticals Inc’s share price target?

The average share price target for Madrigal Pharmaceuticals Inc is 519.64. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is $590.00 ,and the lowest forecast is $392.00. The average share price target represents 7.01% Increase from the current price of $485.58.

What do analysts say about Madrigal Pharmaceuticals Inc?

Madrigal Pharmaceuticals Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 17 Wall Streets Analysts.

How can I buy shares of Madrigal Pharmaceuticals Inc?

To buy shares of GB:0JXI, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Madrigal Pharmaceuticals (0JXI) Share Forecast & Price Target

0JXI Analyst Ratings

0JXI Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Madrigal Pharmaceuticals

0JXI Analyst Recommendation Trends

0JXI Financial Forecast

0JXI Earnings Forecast

0JXI Sales Forecast

0JXI Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts